Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Calic, P. P. S., Ashton, T. D., Mansouri, M., Loi, K., Jarman, K. E., Qiu, D., Lehane, A. M., Roy, S., Rao, G. P., Maity, B., Wittlin, S., Crespo, B., Gamo, F.-J., Deni, I., Fidock, D. A., Chowdury, M., de Koning-Ward, T. F., Cowman, A. F., Jackson, P. F., … Sleebs, B. E. (2024). Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3. European Journal of Medicinal Chemistry, 276, 116677. https://doi.org/10.1016/j.ejmech.2024.116677

Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians’ views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology, 59(12), 3641–3649. Portico. https://doi.org/10.1002/ppul.27273

Navi, B. B., Zhang, C., Miller, B., Cushman, M., Kasner, S. E., Elkind, M. S. V., Tirschwell, D. L., Longstreth, W. T., Kronmal, R. A., Beyeler, M., Elm, J., Zweifler, R. M., Tarsia, J., Cereda, C. W., Bianco, G., Costamagna, G., Michel, P., Broderick, J. P., Gladstone, D. J., … Streib, C. (2024). Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke. JAMA Neurology, 81(9), 958. https://doi.org/10.1001/jamaneurol.2024.2404

Rafic, E., Ma, C., Shih, B. B., Miller, H., Yuste, R., Palomero, T., & Etchenique, R. (2024). RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. Journal of the American Chemical Society, 146(19), 13317–13325. https://doi.org/10.1021/jacs.4c01720

Kamel, H., Longstreth, W. T., Tirschwell, D. L., Kronmal, R. A., Marshall, R. S., Broderick, J. P., Aragón García, R., Plummer, P., Sabagha, N., Pauls, Q., Cassarly, C., Dillon, C. R., Di Tullio, M. R., Hod, E. A., Soliman, E. Z., Gladstone, D. J., Healey, J. S., Sharma, M., … Chaturvedi, S. (2024). Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy. JAMA, 331(7), 573. https://doi.org/10.1001/jama.2023.27188

Gotlib, J., Reiter, A., Radia, D. H., Deininger, M. W., George, T. I., Panse, J., Vannucchi, A. M., Platzbecker, U., Alvarez-Twose, I., Mital, A., Hermine, O., Dybedal, I., Hexner, E. O., Hicks, L. K., Span, L., Mesa, R., Bose, P., Pettit, K. M., Heaney, M. L., … DeAngelo, D. J. (2021). Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature Medicine, 27(12), 2192–2199. https://doi.org/10.1038/s41591-021-01539-8